Favourable clinical benefit of PD‐1/PD‐L1 inhibition has been observed in NSCLC patients with TP53 mutations or combinations of KRAS and TP53 mutations in the same tumour independent of TMB.34, 35, 36. The gene discussed is KRAS; the disease is neoplasm.